Gregory Lesinski: Winship Team Publishes Novel CAR/VIPRa T-Cell Therapy in Science
oncodaily - Gregory Lesinski, Associate Director of Basic Research at Winship Cancer Institute of Emory University, shared on LinkedIn by Sarwish Rafiq, Assistant Professor at the Emory University School of Medicine and […]
AI Summary: Researchers published a novel CAR T‑cell approach exploiting the VIP–VIPR pathway that reprograms cells for superior antitumor activity in preclinical models. The Winship team’s paper reports enhanced tumor killing and durability in laboratory studies, flagging a promising route to improve CAR T efficacy in solid tumors — still very early, but intriguing.
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
Frank Vinluan / medcitynews - GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First…
AI Summary: GSK has won FDA approval for its first lung cancer drug, a gene-targeting therapy that validates the company’s heavy investment and recent M&A strategy. The approval follows pivotal trial evidence of clinical benefit and positions GSK competitively in thoracic oncology, offering a new therapeutic choice for patients with the relevant molecular profile.
6-year-old in China dies after experimental treatment, investigation finds, raising questions about the country's gene therapy regulations
livescience - A young girl in China died after being given an experimental gene therapy intended to treat a neurodevelopmental syndrome, an investigation by Science and Retraction Watch revealed.
AI Summary: An investigation found a six‑year‑old patient died following an experimental gene‑editing treatment in China, and that the fatality was not promptly disclosed. The case has reignited scrutiny of the country’s gene therapy oversight and raised urgent questions about trial transparency, consent and regulatory enforcement.